Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 1;29(3):273-281.
doi: 10.4062/biomolther.2020.226.

Differential Signaling and Virus Production in Calu-3 Cells and Vero Cells upon SARS-CoV-2 Infection

Affiliations

Differential Signaling and Virus Production in Calu-3 Cells and Vero Cells upon SARS-CoV-2 Infection

Byoung Kwon Park et al. Biomol Ther (Seoul). .

Abstract

Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) is responsible for the current coronavirus disease 2019 (COVID-19) pandemic. Signaling pathways that are essential for virus production have potential as therapeutic targets against COVID-19. In this study, we investigated cellular responses in two cell lines, Vero and Calu-3, upon SARS-CoV-2 infection and evaluated the effects of pathway-specific inhibitors on virus production. SARS-CoV-2 infection induced dephosphorylation of STAT1 and STAT3, high virus production, and apoptosis in Vero cells. However, in Calu-3 cells, SARS-CoV-2 infection induced long-lasting phosphorylation of STAT1 and STAT3, low virus production, and no prominent apoptosis. Inhibitors that target STAT3 phosphorylation and dimerization reduced SARS-CoV-2 production in Calu-3 cells, but not in Vero cells. These results suggest a necessity to evaluate cellular consequences upon SARS-CoV-2 infection using various model cell lines to find out more appropriate cells recapitulating relevant responses to SARS-CoV-2 infection in vitro.

Keywords: Apoptosis; COVID-19; SARS-CoV-2; STAT1; STAT3; STAT3 phosphorylation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Differential production of SARS-CoV-2 in Vero and Calu-3 cells. Vero and Calu-3 cells (5×104 cells/well in 12-well plates) were cultured in DMEM containing 10% FBS. After overnight culture, cells were washed with PBS and SARS-CoV-2 in PBS at a MOI of 0.1 was added into each well (n=3). After 1 h of incubation, the medium was replenished with DMEM containing 2% FBS. (A) Supernatants of virus-infected cell cultures were collected at the indicated times after virus infection to isolate viral RNAs. Virus replication was quantified by real-time RT-PCR analysis of the SARS-CoV-2 RdRP gene. Copy numbers of the RdRP gene in 1 µL of the cDNA samples were calculated using a standard curve of RdRP cDNA. (B) Supernatants of virus-infected Vero and Calu-3 cells (12-well plates) were collected at the indicated times after virus infection. Virus production was quantified by plaque formation assay. *p<0.05, **p<0.01, ***p<0.001.
Fig. 2
Fig. 2
Effect of SARS-CoV-2 on induction of apoptosis. (A, B) Vero (A) and Calu-3 (B) cells were infected with 0.5 MOI of SARS-CoV-2 or without virus for the indicated times. After 1 h of incubation, the medium was replenished with DMEM containing 2% FBS. After 72 h of incubation, cell lysates were prepared, and Western blot analysis was performed to detect PARP, cleaved Caspase-3, c-Myc, and cyclin D1. β-actin was used as the control.
Fig. 3
Fig. 3
STAT1 and STAT3 phosphorylation in SARS-CoV-2-infected Vero and Calu-3 cells. (A) Vero cells were infected with 0.5 MOI of SARS-CoV-2 (left) or were mock-infected (right) for the indicated times. (B) Calu-3 cells were infected with 0.5 MOI of SARS-CoV-2 (left), indicated MOIs (middle), or were mock-infected cells (right) for the indicated times with the indicated MOIs. Western blotting of the cell lysates was performed with the indicated antibodies. β-actin was used as the control.
Fig. 4
Fig. 4
Effects of pathway-specific inhibitors on SARS-CoV-2-induced STAT1 and STAT3 phosphorylation in Calu-3 cells. (A) Calu-3 cells were pretreated with 0.1% DMSO, 10 μM PD169316, 25 μM PD98059, 25 μM SP600125, 25 μM AG490, or 1 μM JAK inhibitor I for 30 min. (B) Calu-3 cells were pretreated with the indicated concentrations of S3I-201 inhibitor for 30 min. The cells were washed with PBS and then infected with SARS-CoV-2 in PBS at 0.5 MOI. After 1 h of incubation, the medium was replenished with DMEM containing 2% FBS. (C) Calu-3 cells were treated with 0.1% DMSO, 10 μM PD169316, 25 μM PD98059, 25 μM SP600125, 25 μM AG490, 1 μM JAK inhibitor I, or 20 μM S3I-201. (A-C) After 48 h of incubation, cell lysates were prepared, and Western blotting was performed with the indicated antibodies. (D) Calu-3 cells were pretreated with 0.1% DMSO, 25 μM AG490, 1 μM JAK inhibitor I, 20 μM S3I-201, or 10 μM STA-21 for 30 min. The cells were washed with PBS and then infected with SARS-CoV-2 in PBS at 0.5 MOI. After 1 h of incubation, the medium was replenished with DMEM containing 2% FBS. After 48 h of incubation, the cells were treated with 20 nM Leptomycin B for 3 h. To evaluate phosphorylation and localization of STAT3, cells were fixed with 4% paraformaldehyde, stained with phospho-STAT3 antibody (green), and observed by confocal microscopy. Hoechst 33258 was used for nuclei staining (blue).
Fig. 5
Fig. 5
Production of SARS-CoV-2 in Vero and Calu-3 cells in the presence of pathway-specific inhibitors. (A, B) Vero cells were cultured overnight in 24-well plates and pretreated with PBS, 0.1% DMSO, 1 μM JAK inhibitor I, 20 μM S3I-201, or 10 μM STA-21 for 30 min. The cells were washed with PBS and infected with SARS-CoV-2 in PBS (0.1 MOI). After 1 h of incubation, the medium was replenished with DMEM containing 2% FBS. After 3 days of incubation, virus production was measured by the plaque formation assay (A) and real-time RT-PCR analysis of the SARS-CoV-2 RdRP gene (B). (C, D) Calu-3 cells in 12-well plates were pretreated with PBS, 0.1% DMSO, 1 μM JAK inhibitor I, 20 μM S3I-201, or 10 μM STA-21 for 30 min. The cells were washed with PBS and infected with SARS-CoV-2 in PBS at 0.1 MOI. After 72 h of incubation, virus production was measured by the plaque formation assay (C) and real-time RT-PCR analysis of the SARS-CoV-2 RdRP gene (D). *p<0.05, **p<0.01, ***p<0.001 compared to virus only controls.
Fig. 6
Fig. 6
Possible STAT3 signal transduction pathways in SARS-CoV-2-infected Vero Cells and Calu-3 cells. SARS-CoV-2 enters host cells by binding to the cell surface receptor ACE2. Cellular responses to SARS-CoV-2 differ depending on the host cell type. In Vero cells, STAT1 and STAT3 are dephosphorylated within 2 days after virus infection and apoptosis occurs as observed by an increase in the amount of cleaved PARP and cleaved Caspase-3. In contrast, in Calu-3 cells, phosphorylation of STAT1 and STAT3 persists for days after virus infection and no prominent apoptosis occurs, but induction of proliferation-associated Cyclin D1 and c-Myc proteins occurs. Phosphorylation and dimerization of STAT3 are required for virus production in Calu-3 cells. Possible regulation of the STAT3 signaling pathways by SARS-CoV-2 proteins is shown.

References

    1. Biondi R. M., Nebreda A. R. Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem. J. 2003;372:1–13. doi: 10.1042/bj20021641. - DOI - PMC - PubMed
    1. Chandra V., Kar-Roy A., Kumari S., Mayor S., Jameel S. The hepatitis E virus ORF3 protein modulates epidermal growth factor receptor trafficking, STAT3 translocation, and the acute-phase response. J. Virol. 2008;82:7100–7110. doi: 10.1128/JVI.00403-08. - DOI - PMC - PubMed
    1. Chang Z., Wang Y., Zhou X., Long J. E. STAT3 roles in viral infection: antiviral or proviral? Future Virol. 2018;13:557–574. doi: 10.2217/fvl-2018-0033. - DOI - PMC - PubMed
    1. Danthi P. Viruses and the diversity of cell death. Annu. Rev. Virol. 2016;3:533–553. doi: 10.1146/annurev-virology-110615-042435. - DOI - PubMed
    1. Datta P. K., Liu F., Fischer T., Rappaport J., Qin X. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics. 2020;10:7448–7464. doi: 10.7150/thno.48076. - DOI - PMC - PubMed